Isocoformycin is a structural isomer of coformycin which has been demonstrated to be a potent inhibitor of adenosine deaminase. Isocoformycin showed a weaker inhibition of this enzyme than coformycin; the binding of coformycin to enzyme was irreversible, but isocoformycin inhibition was competitive with substrate. The Ki value of isocoformycin was 4.5-10x 10_e M. Following intraperitoneal injection of isocoformycin in mice, the adenosine deaminase activity of homogenates of several organs was determined and the following EDoo values (50% inhibition doses) were observed: 29 mg/kg for thymus, 13 mg/kg for spleen, 80 mg/kg for liver and 20 mg/kg for kidney. The inhibition of adenosine deaminase in rabbit blood in vitro was also tested in comparison with coformycin.
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UMEZAWA et al. '-2> reported that coformycin is a strong inhibitor of adenosine deaminase (EC 3,5,4,4) and exhibits strong synergistic effects with formycin A and arabinosyl adenine in inhibition of the growth of bacteria, EHRLICH carcinoma cells and YOSHIDA rat sarcoma cells.
Moreover, coformycin ( Fig. 1) had a unique structure') as an inhibitor of adenosine deaminase.
2'-Deoxycoformycin" also exhibits a strong inhibition of the enzyme and strong synergistic effects with adenosine analogs'"). These inhibitors bind tightly to adenosine deaminase'0I. The effect or toxicity of such strongly bound inhibitors may persist for longer periods than that of inhibitors which inhibit the enzyme competitively. We have described the synthesis of isocoformycin Fig. 1 )"'. This compound was found to be a competitive inhibitor of adenosine deaminase.
In this paper, studies on the inhibition of adenosine deaminase by isocoformycin in vitro and in vivo are reported.
Materials and Methods
Formycin A and coformycin were supplied by Meiji Seika Co. Adenosine was obtained from a commercial source and purified by recrystallization from water. 9-fl-D-Arabinofuranosyladenine (ara-A) was obtained from Drug Research and Development, National Cancer Institute, Bethesda, U.S.A. Adenosine deaminase (Type I, 230 units/mg protein) of calf intestinal mucosa was purchased from Sigma Chemical Co. 9-/3-n-Arabinofuranosylhypoxanthine (ara-H) was synthesized from ara-A by oxidation with sodium nitrite. Kinetic Studies ACKERMANN-POTTER analysis was carried out by the method described by CHA et al.102 Varied amounts of adenosine deaminase were incubated in a total volume of 1.9 ml of 50 mm sodium phosphate buffer, pH 7.5, containing isocoformycin (or coformycin) at varied concentrations. After incubation for 50 minutes at room temperature, 0.1 ml of 2 mm adenosine was added and the reaction was followed by measuring the decrease in absorbancy at 265 nm at room temperature. Alternatively, the enzyme reaction was carried out without preincubation with isocoformycin and the results examined by a LINEWEAVER-BURK Plot. When ara-A or formycin A was used as the substrate, the decrease in the optical density at 259 nm or 295 nm, respectively was recorded.
Inhibition of Adenosine Deaminase by Isocoformycin in vivo Isocoformycin dissolved in 0.9% NaCI solution was injected intraperitoneally to ddY mice at 100 mg/kg, 25 mg/kg and 6.25 mg/kg. For each dose, 3 mice were used. One hour after the injection, mice were sacrificed and thymus, spleen, liver and kidney were frozen immediately and weighed. They were homogenized in 2 volumes of 50 mm cold Tris-HCI buffer (pH 7.5) with a motor-driven glass pestle. Fifty ,u1 of each homogenate were added to 45011 of a reaction mixture containing 501.1 of 0.5 M Tris-HCl buffer (pH 7.5) and 5011 of 10 mm [3H]-ara-A (0.3 pci/assay) at 0°C. The mixture was incubated for 5, 10, 20 and 30 minutes at 37°C. The reaction was stopped by heating in a boiling water bath for 3 minutes and 10014 aliquots were subjected to high-voltage paper electrophoresis (3,500 V, 20 minutes) using Toyo Filter Paper No. 51. By this method, a complete separation of ara-H from ara-A was obtained: Rm of ara-A, 0.70-0.73; Rm of ara-H, 0.20-0.23; Rm is the mobility of a sample relative to alanine as standard. The area of ara-H was cut out and determined by liquid scintillation counting. From the results, the doses which caused the reduction of adenosine deaminase activities of thymus, spleen, liver and kidney to 50% of the control were obtained.
Inhibition of Adenosine Deaminase in Rabbit Blood by Isocoformycin or Coformycin in vitro One ml of an aqueous solution of isocoformycin (or coformycin) at varied concentrations was added to I ml of formycin A solution (326,ug/ml) or I ml of ara-A solution (336 ,ug/ml). The reaction was started by addition of 1.0 ml of rabbit blood (10 ml of rabbit blood was taken into a syringe containing 100 units heparin) and the mixture incubated at 37°C for 10 minutes. The reaction was stopped by addition of 3.0 ml of methanol and the precipitate removed by centrifugation; 6 p1 of the supernatant were subjected to high pressure liquid chromatography (JASCO FLC-A10): solid phase, JASCO CV-01-500 (2.3 mm x 500 mm); mobile phase, 0.01 M KH2PO4 of pH 6.0 for the analysis of formycin or at pH 4.7 for the analysis of ara-A; flow rate, 0.5 ml/min; column pressure, 100 kg/cm2; column temperature, ambient; detecter, UVIDEC-100 (wave length 280 nm); chart speed, 0.5 cm/min.
Result Kinetic Studies
Coformycin has been reported by CHA et al.102 to be a tight-binding inhibitor of adenosine deaminase. The binding of isocoformycin was examined by ACKERMANN-POTTER analysis. As shown in Fig. 2 , coformycin was a stoichiometric inhibitor, but isocoformycin was not a tight-binding inhibitor. The inhibition by isocoformycin was competitive with the substrate adenosine, as illustrated in Fig. 3 . The Ki value for isocoformycin was obtained by a LINEWEAVER-BURK plot of the results. Table I indicates the Ki values of isocoformycin and coformycin when adenosine, ara-A or formycin A were used as the substrate. 
Discussion
As shown in Fig. 6 deaminase much more strongly than isocoformycin. As shown by the extremely small Ki value the binding of coformycin to the enzyme is apparently irreversible. Although the activity of isocoformycin is much weaker than that of coformycin, the Ki value for adenosine deaminase was 4.5 -10.0 x 10-e M and it is still a strong inhibitor of the enzyme. A small difference in Ki values was observed depending on substrates such as formycin, adenosine or ara-A. The Ki value should be independent of substrate and the small differences described previously may be due to experimental error.
Both coformycinz'3j and isocoformycin exhibit inhibition of adenosine deaminase in vivo. The administration of 10-100 mg/kg decreased the deamination of ara-A in various organs to 50% of the control. As will be reported subsequently, isocoformycin has a much lower toxicity than coformycin. 
